AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,145 | -34.5% | 20,597 | +4.9% | 0.00% | -100.0% |
| Q2 2023 | $323,663 | +105.4% | 19,640 | +14.2% | 0.00% | – |
| Q1 2023 | $157,561 | +23.5% | 17,201 | -3.4% | 0.00% | – |
| Q4 2022 | $127,580 | +57.5% | 17,801 | +10.6% | 0.00% | – |
| Q3 2022 | $81,000 | +1520.0% | 16,101 | +657.3% | 0.00% | – |
| Q2 2022 | $5,000 | -66.7% | 2,126 | 0.0% | 0.00% | – |
| Q1 2022 | $15,000 | -16.7% | 2,126 | -2.9% | 0.00% | – |
| Q4 2021 | $18,000 | -14.3% | 2,189 | +1.1% | 0.00% | – |
| Q3 2021 | $21,000 | -69.6% | 2,166 | -78.8% | 0.00% | – |
| Q2 2021 | $69,000 | -31.7% | 10,213 | -8.9% | 0.00% | – |
| Q1 2021 | $101,000 | +34.7% | 11,213 | 0.0% | 0.00% | – |
| Q4 2020 | $75,000 | -6.2% | 11,213 | -29.7% | 0.00% | – |
| Q3 2020 | $80,000 | +66.7% | 15,951 | +165.8% | 0.00% | – |
| Q2 2020 | $48,000 | +700.0% | 6,000 | +757.1% | 0.00% | – |
| Q1 2020 | $6,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 3,102,673 | $4,468,000 | 0.92% |
| JW Asset Management, LLC | 444,439 | $640,000 | 0.33% |
| BRANDES INVESTMENT PARTNERS, LP | 7,052,720 | $10,157,000 | 0.24% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,722,241 | $3,920,000 | 0.15% |
| Tekla Capital Management LLC | 814,588 | $1,173,000 | 0.05% |
| INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV | 34,750 | $50,000 | 0.04% |
| Brown Capital Management | 1,400,007 | $2,016,000 | 0.02% |
| ACADIAN ASSET MANAGEMENT LLC | 843,975 | $1,217,000 | 0.01% |
| WEDBUSH SECURITIES INC | 35,535 | $51,000 | 0.01% |
| Close Asset Management Ltd | 15,000 | $22,000 | 0.00% |